Everyone agrees there are enormous risks inherent to drug discovery, and that’s made funding and sustaining the earliest phases of discovery extremely challenging, but with so much at stake for patients, thought leaders in science and business are coming together to address this.

By pairing scientific excellence with efficient, decentralized novel business models that are less reliant on traditional infrastructure, these pioneers are establishing organizations that fully leverage collaborative networks and are stocking the pipelines of tomorrow’s pharmacopeia.

Contributors from three such organizations, BioMotiv, Tri-I Institutional Therapeutics Discovery Institute, and the Milner Therapeutics Institute, along with Charles River, discussed their missions and execution strategies with Drug Discovery World.